Investors bid up post-Medivation M&A targets BioMarin, Incyte and more

When one M&A door closes, many potential windows open. At least that was the operative theory Monday after Pfizer ($PFE) said it had wrapped up a $14 billion deal for Medivation ($MDVN), leaving a gaggle of biopharma bidders empty-handed.

Investors bid up shares in more than a half-dozen biotechs pegged as potential backup targets: BioMarin ($BMRN), said to be among Sanofi’s ($SNY) Plan B, was one of the big movers. So was Incyte, which, like Medivation, has a cancer pipeline and a marketed oncology product--albeit a smaller one--in Jakavi, which is co-marketed with Novartis ($NVS). Goldman Sachs ($GS) analysts highlighted Incyte ($INCY) in particular; that company’s shares were up more than 6% by day’s end.

 

Tesaro ($TSRO), the company with a PARP inhibitor that could rival Medivation’s talazoparib, also rose. So did Clovis Oncology ($CLVS), despite a big setback recently, when it canned an oncology candidate, rociletinib, that would have competed with AstraZeneca’s first-in-class lung cancer med, Targrisso.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Given that a who's who of Big Pharma and Big Biotech was apparently kicking tires at Medivation--with Sanofi, Gilead Sciences ($GILD) and Celgene ($CELG) reportedly among the last round of bidders--plenty of large-scale buyers are out there chasing deals.

“Every relatively small biotech firm is up” because of the Medivation acquisition news, Jacob Kilstein, an analyst at Argus Research Company, told Bloomberg. “They could become a target as well.”

It’s not as if this was the first time market-watchers thought about a post-Medivation future, however. All these targets and more have been bandied about as prospects. In a note earlier this month, Credit Suisse analysts tagged BioMarin, which focuses on drugs for rare genetic disorders, but also named Alexion Pharmaceuticals ($ALXN), whose ultra-orphan drug Soliris is noted for its status as the most expensive in the world. Alexion also has a couple of newer ultra-rare-disease meds.

Credit Suisse’s Vamil Divan predicts that all these and more are either in play already or will soon come into a larger company’s sights. He expects a series of small- and mid-sized deals up to $25 billion, given “the need many larger companies have to try and boost their growth prospects.”

BioMarin, which boasts a portfolio of 5 meds and more in the pipeline, ended Monday with a market cap of more than $18 billion, several billion larger than Pfizer’s Medivation score, while Incyte is now valued at more than $16 billion. One reason Goldman Sachs called it out is this: Its epacadostat candidate is entering Phase III combo studies alongside Merck immuno-oncology med Keytruda, and the Incyte med is under study in a range of other tumor types, too.

Alexion is a richer prospect at $27 billion. Tesaro, on the other hand, is more bite-sized: Even after yesterday’s upward tick, the company’s market cap ended at $5.3 billion. On that smaller end of the scale, Credit Suisse also pointed to Seattle Genetics ($SGEN), Alder Therapeutics ($ALDR), Intercept Pharmaceuticals ($ICPT), Ultragenyx ($RARE) and more.

Related Articles:
After Medivation? Alexion, BioMarin, Incyte could be Big Pharma's next targets
BioMarin climbs on rumors it may be Sanofi's Medivation backup
Pay up, Sanofi: Tesaro's PARP data give Medivation deal expectations a boost
Alexion's Soliris didn't ace its myasthenia gravis trial, but it might still win big sales
Clovis bags rociletinib, leaving AZ's Tagrisso with a clear path to $3B
AstraZeneca's $3B push for Tagrisso gets leg up from Clovis setback

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.